
The Chicago-based startup designed its minimally invasive system with a novel nitinol scaffold that perforates blood clots and infuses them with tissue plasminogen activator (TPA), a thrombolytic drug commonly referred to as a clot-buster.
Flow Medical recently offered Medical Design & Outsourcing our first good look at the prototype with some images that we’re sharing here.
“We wanted to build a device where you can perform pulmonary angiograms through the device with a scaffold that would expand into the clot and deliver thrombolytic drugs. That’s a lot of things to try and do in a relatively small-profile device,” Flow Medical co-founder and CEO Jennifer Fried said in an interview. .
Flow Medical is now starting verification and validation (V&V) testing, supported by a $5 million seed round the company just closed.